FDA Perturbed By Provention's Teplizumab Type 1 Diabetes Drug

Concerns Over Pharmacokinetics Data

 
• By Kevin Grogan
  
delays
Teplizumab approval pathway not so clear now • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas